Corona Virus Infection Clinical Trial
Official title:
The Role of Social Media as an Information Source in Covid19 Pandemic
According to the data of February 2020, in Turkey with a population of 83.9 million, internet and social media usage percentage to population are 74% and 64% respectively. Although previous researches have investigated the effect of social media on different medical situations, there is no study focused role of social media on patients' behavior and information source during the COVID-19 pandemic. In the present study, it is aimed to reveal the impact of social media on patients' attitudes and information sources during the COVID-19 pandemic.
The coronavirus disease (COVID-19) outbreak was first diagnosed in late December 2019 in
Wuhan at China's Hubei province. After four months, coronavirus infection has spread to 6
continents and 185 countries, with a dramatic increase of almost 3 million people have been
infected and more than 200,000 people died.JHM As a result of the pandemic, the closure of
borders, social isolation, and the crushing of health systems under an excessive load,
peoples search different ways to achieve proper information regarding protecting themselves
from this disaster including government announcements, hospitals, private doctors, and social
media.
According to the data of February 2020, in Turkey with a population of 83.9 million, internet
and social media usage percentage to population are 74% and 64% respectively. Social media is
the most frequently translated way of informing due to its quick, cheap, and easy access
potential.
Although previous researches have investigated the effect of social media on different
medical situations, there is no study focused role of social media on patients' behavior and
information source during the COVID-19 pandemic. In the present study, it is aimed to reveal
the impact of social media on patients' attitudes and information sources during the COVID-19
pandemic.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04578210 -
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
|
Phase 1/Phase 2 | |
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Completed |
NCT04720794 -
A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
|
N/A | |
Enrolling by invitation |
NCT04659486 -
Adolescents With COVID-19/MIS-C at HCFMUSP
|
N/A | |
Completed |
NCT04598620 -
Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
|
||
Completed |
NCT05517941 -
Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient
|
N/A | |
Recruiting |
NCT04480333 -
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
|
Phase 1 | |
Recruiting |
NCT04565782 -
Corona Virus Infection Among Liver Transplant Recipients
|
||
Active, not recruiting |
NCT04558476 -
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation
|
Phase 2 | |
Completed |
NCT05639998 -
BBV152/BBV154 Heterologus Prime-Boost Study
|
Phase 2 | |
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Completed |
NCT05736926 -
Anal Fissure Among Survivors of COVID-19 Virus Infection.
|
||
Completed |
NCT04523246 -
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
|
Early Phase 1 | |
Withdrawn |
NCT04386447 -
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
|
Phase 2 | |
Recruiting |
NCT04583566 -
Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
|
||
Completed |
NCT04643678 -
Anakinra in the Management of COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04579588 -
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
|
||
Terminated |
NCT03331445 -
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
|
Phase 2 | |
Recruiting |
NCT04573348 -
T Cells Response to SARS COV 2 Peptides
|